BlackRock’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-3,004,210
| Closed | -$4.78M | – | 5430 |
|
|
2024
Q1 | $4.78M | Sell |
3,004,210
-173,955
| -5% | -$258K | ﹤0.01% | 3685 |
|
|
2023
Q4 | $2.73M | Sell |
3,178,165
-661,714
| -17% | -$581K | ﹤0.01% | 3921 |
|
|
2023
Q3 | $4.11M | Sell |
3,839,879
-793,126
| -17% | -$1.64M | ﹤0.01% | 3731 |
|
|
2023
Q2 | $12M | Buy |
4,633,005
+526,863
| +13% | +$1.88M | ﹤0.01% | 3333 |
|
|
2023
Q1 | $16.8M | Sell |
4,106,142
-53,620
| -1% | -$248K | ﹤0.01% | 3057 |
|
|
2022
Q4 | $20.9M | Buy |
4,159,762
+93,185
| +2% | +$584K | ﹤0.01% | 3021 |
|
|
2022
Q3 | $53.2M | Buy |
4,066,577
+193,828
| +5% | +$2.94M | ﹤0.01% | 2393 |
|
|
2022
Q2 | $49.6M | Buy |
3,872,749
+1,033,075
| +36% | +$14.3M | ﹤0.01% | 2501 |
|
|
2022
Q1 | $43.3M | Buy |
2,839,674
+58,883
| +2% | +$918K | ﹤0.01% | 2668 |
|
|
2021
Q4 | $49.3M | Buy |
2,780,791
+335,959
| +14% | +$6.45M | ﹤0.01% | 2672 |
|
|
2021
Q3 | $51.4M | Buy |
2,444,832
+145,477
| +6% | +$3.2M | ﹤0.01% | 2645 |
|
|
2021
Q2 | $45.3M | Sell |
2,299,355
-465,225
| -17% | -$10.9M | ﹤0.01% | 2765 |
|
|
2021
Q1 | $80.4M | Buy |
2,764,580
+238,964
| +9% | +$6.69M | ﹤0.01% | 2314 |
|
|
2020
Q4 | $76.5M | Buy |
2,525,616
+81,177
| +3% | +$1.78M | ﹤0.01% | 2235 |
|
|
2020
Q3 | $38.9M | Buy |
2,444,439
+158,965
| +7% | +$2.9M | ﹤0.01% | 2444 |
|
|
2020
Q2 | $45.1M | Buy |
2,285,474
+33,968
| +2% | +$649K | ﹤0.01% | 2312 |
|
|
2020
Q1 | $27.8M | Sell |
2,251,506
-56,780
| -2% | -$927K | ﹤0.01% | 2429 |
|
|
2019
Q4 | $42.7M | Buy |
2,308,286
+1,653,937
| +253% | +$24.2M | ﹤0.01% | 2460 |
|
|
2019
Q3 | $9.06M | Buy |
654,349
+333,604
| +104% | +$5.01M | ﹤0.01% | 3255 |
|
|
2019
Q2 | $4.7M | Buy |
+320,745
| New | +$4.69M | ﹤0.01% | 3549 |
|
BlackRock's NGM Position: Q2 2024 in Review
BlackRock sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 3,004,210 shares — an estimated $4.78M sold.
BlackRock first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $80.4M in Q1 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- BlackRock reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- BlackRock sold 3,004,210 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $4.78M.
- BlackRock first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
- BlackRock's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $80.4M in Q1 2021.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on BlackRock's 13F filing for Q2 2024, filed 13 Aug 2024.